Fluticasone propionate/salmeterol (Advair HFA) vs Salbutamol HFA-152a

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline

Fluticasone propionate/salmeterol (Advair HFA)

Marketed by GlaxoSmithKline

Approved in Asthmacombination (ICS + LABA)
Partial signal

NCT00448435 · Phase 3 · completed

The 51 participants were randomized to treatment sequences and received an active comparator, but the trial was not blinded. Its primary morning PEF endpoint met the prespecified equivalence margin, while the endpoint was a physiologic surrogate rather than a hard clinical or endoscopic measure, supporting a moderate evidence grade.

Reported efficacy

Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) (met)

Result source: NCT00448435

Salbutamol HFA-152a

Developed by GlaxoSmithKline

Phase 3 in Asthmasmall molecule
Weak signal

NCT06261957 · Phase 3 · completed

The trial randomized 471 participants and used quadruple blinding with an active salbutamol comparator. Its primary clinical safety endpoint was the number of participants with adverse events. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events (AEs) During Run-in Period" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: April 2027 · NCT06433921 (registry estimate)

Reported efficacy

Number of participants with Adverse Events (AEs) (Up to 3 months): Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results). (not_applicable)

Result source: NCT06261957

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFluticasone propionate/​salmeterol (Advair HFA)Salbutamol HFA-152a
Severe exacerbations, annualised rate1.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699—Not reported
Trough FEV1, change—Not posted · NCT00646620—Not reported
ACQ-5, change—Not posted · NCT00646620—Not reported
OCS dose reduction—Not posted · NCT00646620—Not reported

Severe exacerbations, annualised rate

Fluticasone propionate/​salmeterol (Advair HFA)
1.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699
Salbutamol HFA-152a
—Not reported

Trough FEV1, change

Fluticasone propionate/​salmeterol (Advair HFA)
—Not posted · NCT00646620
Salbutamol HFA-152a
—Not reported

ACQ-5, change

Fluticasone propionate/​salmeterol (Advair HFA)
—Not posted · NCT00646620
Salbutamol HFA-152a
—Not reported

OCS dose reduction

Fluticasone propionate/​salmeterol (Advair HFA)
—Not posted · NCT00646620
Salbutamol HFA-152a
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Salbutamol HFA-152a
Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results). NCT06261957 · Phase 3 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Fluticasone propionate/salmeterol (Advair HFA): 4 of 4 rows · Salbutamol HFA-152a: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFluticasone propionate/​salmeterol (Advair HFA)Salbutamol HFA-152a
Dropout rate
—50/100 mcg/daya
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
—50/100 mcg/day
NCT00448435 · Phase 3 · Asthma · phase 3
26.5%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
0%
NCT00449046 · Phase 3 · registry result, not featured evidence
—800 ugb
NCT06433908 · Phase 1 · registry result, not featured evidence
show 1 more result
—200 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—50/100 mcg/daya
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
—50/100 mcg/day
NCT00448435 · Phase 3 · Asthma · phase 3
3.3%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
—
NCT00449046 · Phase 3 · registry result, not featured evidence
—800 ugb
NCT06433908 · Phase 1 · registry result, not featured evidence
show 1 more result
—200 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
Serious AEs
0%50/100 mcg/daya
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
0%50/100 mcg/day
NCT00448435 · Phase 3 · Asthma · phase 3
4.6%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
—
NCT00449046 · Phase 3 · registry result, not featured evidence
0%800 ugb
NCT06433908 · Phase 1 · registry result, not featured evidence
show 1 more result
3.3%200 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
50/100 mcg/daya
upper respiratory tract inflammation 13.7%
nasopharyngitis 3.9%
stomatitis 3.9%
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
50/100 mcg/day
upper respiratory tract inflammation 34%
gastroenteritis 14%
nasopharyngitis 14%
NCT00448435 · Phase 3 · Asthma · phase 3
250/50 mcg BID
upper respiratory tract infection 20.3%
headache 18.3%
nasopharyngitis 17.6%
NCT00452699 · Phase 4 · registry result, not featured evidence
asthma 20%
bronchitis 20%
laryngopharyngitis 20%
NCT00449046 · Phase 3 · registry result, not featured evidence
800 ugb
catheter site related reaction 30%
headache 16.7%
cough 10%
NCT06433908 · Phase 1 · registry result, not featured evidence
show 1 more result
200 ug
catheter site haematoma 16.7%
headache 10%
abdominal pain 6.7%
NCT06433908 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fluticasone propionate/salmeterol (Advair HFA)

Morning PEF Change L/Min 14.3 vs 17.1 SLM + FP L50/100 mcg/day
absolute change · L
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Predicted 5.38% (n=48) vs 6.73% (n=48) SLM + FP50/100 mcg/day
absolute change · percentage points
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Personal Best 5.01% (n=48) vs 6.46% (n=48) SLM + FP50/100 mcg/day
absolute change · percentage points
NCT00448435 · Phase 3 · Asthma · phase 3
Evening PEF Change L/Min 16.3 vs 15.8 SLM + FP L/min50/100 mcg/day
absolute change · L/min
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Circadian Variation 0.06% (n=48) vs -0.08% (n=48) SLM + FP50/100 mcg/day
absolute change · percentage points
NCT00448435 · Phase 3 · Asthma · phase 3
Symptom-Free Nights and 91.7% (n=48) vs 81.3% (n=48) SLM + FP @ 4wk50/100 mcg/day
absolute value · percentage points
After 4 Weeks of Treatment
NCT00448435 · Phase 3 · Asthma · phase 3
Rescue Medication-Free Nights 93.8% (n=48) vs 87.5% (n=48) SLM + FP @ 4wk50/100 mcg/day
responder rate · % of participants
After 4 Weeks of Treatment
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Change L/Min 3 L/min @ 30wk50/100 mcg/day
absolute change · L/min
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Predicted 1.46% (n=50) @ 30wk50/100 mcg/day
absolute change · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Personal Best 1.29% (n=50) @ 30wk50/100 mcg/day
absolute change · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Evening PEF Change L/Min 2.7 L/min @ 30wk50/100 mcg/day
absolute change · L/min
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Circadian Variation -0.37% (n=50) @ 30wk50/100 mcg/day
absolute change · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3

+ 12 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone propionate/salmeterol (Advair HFA)'s landscape · Salbutamol HFA-152a's landscape